AI Signal: Sign In to See
Clover To Present at World Vaccine Congress Washington 2022Apr 12th, 2022 6:30 EST
SHANGHAI, China, April 12, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that Igor Smolenov, Senior Vice President, Global Clinical Development, will deliver a presentation at the World Vaccine Congress Washington 2022. The presentation will include data on SCB-2019 (CpG 1018/Alum), Clover’s adjuvanted protein-based COVID-19 vaccine candidate.
Presentation details are as follows:
|Workshop Title:||Vaccine Technology|
|Presenter:||Igor Smolenov, SVP, Global Clinical Development, Clover Biopharmaceuticals|
|Presentation Title:||Clover’s adjuvanted protein-based vaccine: efficacy against SARS-CoV-2 variants and duration of protection|
|Session Date and Time:||April 18, 2022, 3:15 – 4:30 PM EST|
|Location:||Meeting Level 4, Liberty Salon J|
For more information or to register, visit the World Vaccine Congress website.
About SCB-2019 (CpG 1018/Alum)Employing the Trimer-Tag™ technology platform, Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein (referred to as S-Trimer™) based on the original strain of the SARS-CoV-2 virus. Clover created its COVID-19 vaccine candidate by combining SCB-2019 with Dynavax’s (Nasdaq: DVAX) CpG 1018 advanced adjuvant and aluminum hydroxide (alum).
About Clover BiopharmaceuticalsClover Biopharmaceuticals is a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates. The Trimer-Tag™ technology platform is a product development platform for the creation of novel vaccines and biologic therapies. Clover leveraged the Trimer-Tag™ technology platform to become a COVID-19 vaccine developer and created SCB-2019 (CpG 1018/Alum) to address the COVID-19 pandemic caused by SARS-CoV-2.
Cindy MinSVP, Public Affairs[email protected]
Naomi EichenbaumVP, Investor Relations[email protected]